FIELD: chemistry.
SUBSTANCE: invention relates to a complex containing an insulin conjugate which contains native insulin or its polypeptide analogue conjugated with a modifying group, where the polypeptide analogue exhibits similar activity relative native insulin and where the modifying group contains a polyalkylene gycol component (PAG) and an alkyl component and a cation, where the insulin conjugate forms a complex with a divalent cation of a group II metal or transition metal. The invention also relates to pharmaceutical compositions containing such complexes and their preparation methods. The invention also relates to fatty acid compositions for administration of complexes of conjugates of disclosed insulin compounds.
EFFECT: design of an efficient method of preparing pharmaceutical compositions containing an insulin conjugate.
60 cl, 42 dwg, 100 ex
| Title | Year | Author | Number |
|---|---|---|---|
| INSULIN-OLIGOMER CONJUGATES, PREPARATIONS AND APPLICATIONS THEREOF | 2005 |
|
RU2527893C2 |
| SOLID PHARMACEUTICAL COMPOSITION (VERSIONS) AND METHOD FOR CONTROLLING GLUCOSE CONCENTRATION THEREWITH, METHOD FOR PREPARING SOLID PHARMACEUTICAL COMPOSITIONS (VERSIONS), TABLET (VERSIONS) AND METHOD FOR MAKING AMORPHOUS PARTICLES | 2008 |
|
RU2453332C2 |
| SITE-SPECIFIC INSULIN CONJUGATE | 2014 |
|
RU2677800C2 |
| ZINC-FREE AND ZINC-DEPLETED INSULIN COMPOSITIONS OF INCREASED STABILITY | 2002 |
|
RU2311922C2 |
| INSULIN ANALOGUE COMPLEX WITH REDUCED AFFINITY TO INSULIN RECEPTOR AND ITS USE | 2018 |
|
RU2779462C2 |
| CARBOHYDRATE-MODIFIED PARTICLES AND POWDERED COMPOSITIONS FOR IMMUNE RESPONSE MODULATION | 2016 |
|
RU2752620C2 |
| PHARMACEUTICAL COMPOSITION CONTAINING INSULIN AND GLUCAGON | 2019 |
|
RU2823246C2 |
| PROLONGED-RELEASE PHARMACEUTICAL COMPOSITIONS FOR PEPTIDE DELIVERY | 2007 |
|
RU2456018C2 |
| COMPLEX CONTAINING HUMAN INSULIN ANALOG AND PHARMACEUTICAL COMPOSITION BASED ON THEREOF | 1995 |
|
RU2152399C2 |
| HALOGEN-STABILISED INSULIN | 2009 |
|
RU2555557C2 |
